{"title":"脓疱性角膜炎:溴莫尼定过敏的一种罕见表现。","authors":"Maitha Al Asmi, Aisha Al Busaidi","doi":"10.4103/ojo.ojo_99_23","DOIUrl":null,"url":null,"abstract":"<p><p>A 32-year-old male, with juvenile open-angle glaucoma on chronic antiglaucoma therapy and recently introduced brimonidine eye drops to the treatment regimen, developed bilateral follicular conjunctivitis with subepithelial infiltrates (SEIs) initially resembling common infectious keratoconjunctivitis entities. The persistent nature of the conjunctivitis, the lack of positive conjunctival cultures, the absence of systemic symptoms, the full resolution of the condition upon discontinuation of antiglaucoma drops, and the commencement of topical steroids, along with the reappearance of SEIs upon reintroducing brimonidine; suggested an immune-mediated drug reaction secondary to a Benzalkonium chloride (BAK) preserved brimonidine tartrate 0.2% formulation. The interval between the initiation of brimonidine and the onset of the drug reaction was 13 months and shortened to 1 week upon re-exposure to the drug. The condition fully resolved without further sequelae off brimonidine. Brimonidine is notoriously known for causing ocular allergic reactions, the most common being follicular conjunctivitis, but very few reports exist describing its adverse effects on the cornea. This case highlights that brimonidine may directly or indirectly induce an immune reaction affecting the cornea in the form of SEIs. Brimonidine is, thus, capable of mimicking more commonly recognized infectious disease entities causing keratoconjunctivitis. This is the second report of a similar manifestation linked to its use.</p>","PeriodicalId":19461,"journal":{"name":"Oman Journal of Ophthalmology","volume":"17 1","pages":"113-116"},"PeriodicalIF":0.0000,"publicationDate":"2023-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10957035/pdf/","citationCount":"0","resultStr":"{\"title\":\"Nummular keratitis: A rare manifestation of brimonidine allergy.\",\"authors\":\"Maitha Al Asmi, Aisha Al Busaidi\",\"doi\":\"10.4103/ojo.ojo_99_23\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>A 32-year-old male, with juvenile open-angle glaucoma on chronic antiglaucoma therapy and recently introduced brimonidine eye drops to the treatment regimen, developed bilateral follicular conjunctivitis with subepithelial infiltrates (SEIs) initially resembling common infectious keratoconjunctivitis entities. The persistent nature of the conjunctivitis, the lack of positive conjunctival cultures, the absence of systemic symptoms, the full resolution of the condition upon discontinuation of antiglaucoma drops, and the commencement of topical steroids, along with the reappearance of SEIs upon reintroducing brimonidine; suggested an immune-mediated drug reaction secondary to a Benzalkonium chloride (BAK) preserved brimonidine tartrate 0.2% formulation. The interval between the initiation of brimonidine and the onset of the drug reaction was 13 months and shortened to 1 week upon re-exposure to the drug. The condition fully resolved without further sequelae off brimonidine. Brimonidine is notoriously known for causing ocular allergic reactions, the most common being follicular conjunctivitis, but very few reports exist describing its adverse effects on the cornea. This case highlights that brimonidine may directly or indirectly induce an immune reaction affecting the cornea in the form of SEIs. Brimonidine is, thus, capable of mimicking more commonly recognized infectious disease entities causing keratoconjunctivitis. This is the second report of a similar manifestation linked to its use.</p>\",\"PeriodicalId\":19461,\"journal\":{\"name\":\"Oman Journal of Ophthalmology\",\"volume\":\"17 1\",\"pages\":\"113-116\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-12-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10957035/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oman Journal of Ophthalmology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/ojo.ojo_99_23\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oman Journal of Ophthalmology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/ojo.ojo_99_23","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
摘要
一名 32 岁的男性患者患有幼年开角型青光眼,长期接受抗青光眼治疗,最近在治疗方案中加入了溴莫尼定滴眼液,结果患上了双侧滤泡性结膜炎,并伴有上皮下浸润(SEIs),最初与常见的感染性角结膜炎相似。结膜炎持续存在,结膜培养未呈阳性,没有全身症状,停用抗青光眼滴眼液后病情完全缓解,开始使用局部类固醇,而重新使用溴莫尼定后又出现了上皮下浸润,这表明这是一种继发于酒石酸溴莫尼定 0.2%苯扎氯铵(BAK)制剂的免疫介导药物反应。从开始使用溴莫尼定到出现药物反应之间的间隔时间为 13 个月,再次接触该药物后,间隔时间缩短为 1 周。在停用溴莫尼定后,病情完全缓解,没有再出现后遗症。溴莫尼定因引起眼部过敏反应而臭名昭著,最常见的是滤泡性结膜炎,但很少有报告描述其对角膜的不良影响。本病例表明,溴莫尼定可能直接或间接诱发以 SEIs 形式出现的影响角膜的免疫反应。因此,溴莫尼定能够模拟更常见的感染性疾病,引起角膜结膜炎。这是第二份与使用溴莫尼定有关的类似表现的报告。
Nummular keratitis: A rare manifestation of brimonidine allergy.
A 32-year-old male, with juvenile open-angle glaucoma on chronic antiglaucoma therapy and recently introduced brimonidine eye drops to the treatment regimen, developed bilateral follicular conjunctivitis with subepithelial infiltrates (SEIs) initially resembling common infectious keratoconjunctivitis entities. The persistent nature of the conjunctivitis, the lack of positive conjunctival cultures, the absence of systemic symptoms, the full resolution of the condition upon discontinuation of antiglaucoma drops, and the commencement of topical steroids, along with the reappearance of SEIs upon reintroducing brimonidine; suggested an immune-mediated drug reaction secondary to a Benzalkonium chloride (BAK) preserved brimonidine tartrate 0.2% formulation. The interval between the initiation of brimonidine and the onset of the drug reaction was 13 months and shortened to 1 week upon re-exposure to the drug. The condition fully resolved without further sequelae off brimonidine. Brimonidine is notoriously known for causing ocular allergic reactions, the most common being follicular conjunctivitis, but very few reports exist describing its adverse effects on the cornea. This case highlights that brimonidine may directly or indirectly induce an immune reaction affecting the cornea in the form of SEIs. Brimonidine is, thus, capable of mimicking more commonly recognized infectious disease entities causing keratoconjunctivitis. This is the second report of a similar manifestation linked to its use.
期刊介绍:
To provide a platform for scientific expression of the Oman Ophthalmic Society and the international Ophthalmic community and to provide opportunities for free exchange of ideas and information. To serve as a valuable resource for ophthalmologists, eye-care providers including optometrists, orthoptists, other health care professionals and research workers in all aspects of the field of visual science.